Fewer people fell ill with and died from tuberculosis in 2025, but the world remains well behind its targets for ending the disease, the World Health Organization said in its Global Tuberculosis Report 2026, published on 12 November. The report credits national governments with stepping up their own spending just as money from international donors shrank.
According to WHO, an estimated 10.6 million people developed TB in 2025 and about 1.13 million died from it. The agency described TB as still the leading cause of death from a single infectious agent.
Deaths down, but targets missed
WHO said TB deaths have fallen by 35% since 2015, which means the world has now reached the first mortality milestone of the End TB Strategy, five years later than planned. The agency estimates that TB treatment has saved some 86 million lives since 2000.
Incidence has moved more slowly. New cases are down 14% since 2015, far short of the 50% cut that was targeted for 2025. Health Policy Watch, reporting on the findings on 13 November, noted that the incidence rate stood at 129 cases per 100,000 people in 2025, compared with 131 a year earlier.
Progress also varies widely by region. WHO's figures show incidence since 2015 has dropped 42% in Europe, 30% in Africa and 18% in South-East Asia, but only 6.6% in the Eastern Mediterranean and not at all in the Western Pacific. In the Americas, incidence rose for a fifth straight year and is now 13% above its 2015 level.
India still carries the biggest share
WHO said 30 countries account for 88% of everyone who developed TB in 2025. Health Policy Watch's breakdown of the report puts India at the top, with roughly a quarter of global cases, followed by Indonesia (10%), the Philippines (6.8%), China (6.5%) and Pakistan (6.4%). The same report said India has made significant progress in reducing cases, and that India and Indonesia recorded the largest increases in domestic TB funding.
Governments step in as donor money falls
Domestic funding for TB rose by 14% to US$ 5.6 billion between 2024 and 2025, WHO said, partly offsetting a fall in international financing of a similar scale. "Many governments have dug deeper into their own budgets to protect the gains they have made," WHO Director-General Dr Tedros Adhanom Ghebreyesus said, calling the continued decline in cases and deaths "very encouraging".
Even so, Health Policy Watch reported that total TB funding of US$ 6.6 billion in 2025 was only about 30% of the US$ 22 billion a year targeted for 2027. Research funding, at US$ 1.2 billion in 2023, was less than a quarter of the US$ 5 billion annual goal, according to WHO.
Gaps in diagnosis and drug-resistant TB
Of the 10.6 million people who fell ill, 8.4 million were diagnosed, leaving about 2.2 million cases undiagnosed or unreported. Only 59% of newly diagnosed patients were tested with a WHO-recommended rapid test, against a target of 100% by 2027.
About 370,000 people developed rifampicin-resistant TB, and only 42% of them received treatment, WHO said. Among those treated, use of the shorter six-month regimen rose from 18% in 2024 to 42% in 2025.
Why it matters
For India, which carries the largest share of the global burden, the report offers both encouragement and a warning: domestic investment is helping, but the global pace of decline is still too slow to meet agreed targets. Dr Katherine Floyd of WHO told Health Policy Watch that reported data did not show a clear negative impact of funding cuts on TB services in 2025, but cautioned that such effects "may be delayed".
What happens next
WHO is urging governments and partners to strengthen political commitment, protect and increase sustainable financing, expand prevention, rapid diagnosis and treatment, and speed up investment in new vaccines, diagnostics and medicines. Progress, the agency said, must become much faster if the world is to get back on track.




